Company Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, for treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-β, for the treatment of pulmonary fibrosis.
Surrozen, Inc. is headquartered in South San Francisco, California.
Country | United States |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 41 |
CEO | Craig Parker |
Contact Details
Address: 171 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 United States | |
Phone | 650 489 9000 |
Website | surrozen.com |
Stock Details
Ticker Symbol | SRZN |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001824893 |
CUSIP Number | 86889P109 |
ISIN Number | US86889P2083 |
Employer ID | 30-1374889 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Craig C. Parker M.B.A. | Chief Executive Officer, President and Director |
Charles Williams | Chief Financial Officer, Chief Operating Officer and Corporate Secretary |
Dr. Li Yang Ph.D. | Executive Vice President of Research |
Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
Dr. Roeland Nusse Ph.D. | Co-Founder and Member of Scientific Advisory Board |
Dr. Calvin Kuo M.D., Ph.D. | Co-Founder and Member of Scientific Advisor |
Esther Jhun | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 8, 2025 | D | Notice of Exempt Offering of Securities |
Apr 2, 2025 | SCHEDULE 13G | Filing |
Apr 2, 2025 | ARS | Filing |
Apr 2, 2025 | SCHEDULE 13G | Filing |
Apr 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 2, 2025 | DEF 14A | Other definitive proxy statements |
Mar 31, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 31, 2025 | 10-K | Annual Report |
Mar 31, 2025 | 8-K | Current Report |
Mar 31, 2025 | SCHEDULE 13G | Filing |